Allergy Revenue Cycle Metrics
Allergy and immunology revenue cycles have three distinct revenue streams that require separate tracking: diagnostic testing (high per-visit revenue, episodic), immunotherapy injections (moderate per-visit revenue, recurring), and biologic drug administration (high per-visit revenue, monthly). Each stream has different benchmarks, collection challenges, and optimization strategies. Practices that track only blended metrics miss the specific revenue leakage points within each stream.
Revenue Per Visit by Service Type
Average revenue per visit in allergy varies dramatically by visit type. New patient evaluation with comprehensive testing: $350 to $600 (E/M plus 40 to 80 tests). Immunotherapy injection visit: $22 to $30 (injection code only) or $60 to $100 (with brief E/M for reaction monitoring). Biologic administration visit: $1,200 to $3,500 (drug plus administration). Established patient follow-up without procedures: $90 to $140 (E/M only).
Blended revenue per visit for a typical allergy practice ranges from $120 to $200, but this number is misleading without the service-type breakdown. A practice generating $120 per visit with strong immunotherapy volume is performing differently than a practice at $120 with no immunotherapy program. Track revenue per visit by service category to identify which streams are underperforming.
Testing Revenue Benchmarks
Track testing revenue per testing encounter, not per visit. The benchmark for a standard percutaneous panel is $140 to $240 (40 to 60 tests at $3.50 to $4.00 per test). Intradermal follow-up sessions should generate $70 to $160 (10 to 20 tests at $7.00 to $8.00 per test). If testing revenue per encounter falls below these ranges, investigate whether test counts are being underbilled, controls are not being captured, or payer reimbursement rates have dropped below contracted amounts.
Compare the number of testing encounters to the number of new patients seen. A healthy conversion rate is 70% to 85% of new patients receiving allergy testing. If less than 60% of new patients are tested, either the referral mix includes too many non-testing conditions or the practice is not capturing testing opportunities when clinically appropriate.
Immunotherapy Revenue
Immunotherapy revenue is the most predictable stream in allergy. Calculate the monthly immunotherapy revenue run rate: (number of active immunotherapy patients) multiplied by (average visits per month) multiplied by (average reimbursement per injection visit). A practice with 150 active immunotherapy patients visiting twice monthly at $26 average generates $7,800 per month, or $93,600 annually, from injections alone.
Track the immunotherapy patient pipeline: new starts per month, patients in build-up, patients in maintenance, and patients completing treatment. A declining pipeline (fewer new starts than completions) signals future revenue reduction. Marketing to referring physicians and converting testing patients to immunotherapy maintains the pipeline.
Days in Accounts Receivable
AR days for allergy should be 25 to 32 days for testing and injection claims. Biologic drug claims may have longer AR due to PA verification and drug pricing reconciliation, with 35 to 45 days being acceptable for drug claims specifically. If blended AR exceeds 35 days, segment by claim type to identify the source. Testing claims should not exceed 30 days under normal circumstances.
Collection Rate and Drug Margin
Net collection rate for allergy testing and injection claims should be 95% or higher. Biologic drug collection is more complex because reimbursement must cover the drug acquisition cost plus a margin. Track drug margin separately: (drug reimbursement minus drug acquisition cost) divided by drug acquisition cost. Medicare ASP+6% provides approximately 6% margin. Commercial contracts should provide 10% to 20% margin. If drug margin drops below 5%, the practice is essentially providing free drug administration services.
Denial Rate by Category
Track denial rates separately for testing claims, injection claims, and drug claims. Testing denial rate target: below 5%. Injection denial rate target: below 3% (these are straightforward claims). Drug claim denial rate target: below 8% (higher due to PA complexity). A blended denial rate above 8% in allergy indicates systemic issues that require root cause analysis by claim category.